Interstitial Lung Disease Research Cluster (#1): Key biomarkers include systemic sclerosis, rheumatoid arthritis, KL-6, acute exacerbation, risk, diagnosis, and nintedanib. This evidence concerns the gene MUC1 and rheumatoid arthritis.